Search Results - "DE WITTE, Theo"

Acquired mutations in TET2 are common in myelodysplastic syndromes by Jansen, Joop H, Langemeijer, Saskia M C, Kuiper, Roland P, Berends, Marieke, Knops, Ruth, Aslanyan, Mariam G, Massop, Marion, Stevens-Linders, Ellen, van Hoogen, Patricia, van Kessel, Ad Geurts, Raymakers, Reinier A P, Kamping, Eveline J, Verhoef, Gregor E, Verburgh, Estelle, Hagemeijer, Anne, Vandenberghe, Peter, de Witte, Theo, van der Reijden, Bert A

“…Myelodysplastic syndromes (MDS) represent a heterogeneous group of neoplastic hematopoietic disorders. Several recurrent chromosomal aberrations have been…”
Get full text

Outcome after relapse of myelodysplastic syndrome and secondary acute myeloid leukemia following allogeneic stem cell transplantation: a retrospective registry analysis on 698 patients by the Chronic Malignancies Working Party of the European Society of Blood and Marrow Transplantation by Schmid, Christoph, de Wreede, Liesbeth C, van Biezen, Anja, Finke, Jürgen, Ehninger, Gerhard, Ganser, Arnold, Volin, Liisa, Niederwieser, Dietger, Beelen, Dietrich, Alessandrino, Paolo, Kanz, Lothar, Schleuning, Michael, Passweg, Jakob, Veelken, Hendrik, Maertens, Johan, Cornelissen, Jan J, Blaise, Didier, Gramatzki, Martin, Milpied, Noel, Yakoub-Agha, Ibrahim, Mufti, Ghulam, Rovira, Montserrat, Arnold, Renate, de Witte, Theo, Robin, Marie, Kröger, Nikolaus

“…No standard exists for the treatment of myelodysplastic syndrome relapsing after allogeneic stem cell transplantation. We performed a retrospective registry…”
Get full text

Adjuvant dendritic cell therapy in stage IIIB/C melanoma: the MIND-DC randomized phase III trial by Bol, Kalijn F., Schreibelt, Gerty, Bloemendal, Martine, van Willigen, Wouter W., Hins-de Bree, Simone, de Goede, Anna L., de Boer, Annemiek J., Bos, Kevin J. H., Duiveman-de Boer, Tjitske, Olde Nordkamp, Michel A. M., van Oorschot, Tom G. M., Popelier, Carlijn J., Pots, Jeanne M., Scharenborg, Nicole M., van de Rakt, Mandy W. M. M., de Ruiter, Valeska, van Meeteren, Wilmy S., van Rossum, Michelle M., Croockewit, Sandra J., Koeneman, Bouke J., Creemers, Jeroen H. A., Wortel, Inge M. N., Angerer, Caroline, Brüning, Mareke, Petry, Katja, Dzionek, Andrzej, van der Veldt, Astrid A., van Grünhagen, Dirk J., Werner, Johanna E. M., Bonenkamp, Johannes J., Haanen, John B. A. G., Boers-Sonderen, Marye J., Koornstra, Rutger H. T., Boomsma, Martijn F., Aarntzen, Erik H. J., Gotthardt, Martin, Nagarajah, James, de Witte, Theo J. M., Figdor, Carl G., de Wilt, Johannes H. W., Textor, Johannes, de Groot, Jan Willem B., Gerritsen, Winald R., de Vries, I. Jolanda M.

“…Autologous natural dendritic cells (nDCs) treatment can induce tumor-specific immune responses and clinical responses in cancer patients. In this phase III…”
Get full text

High log-scale expansion of functional human natural killer cells from umbilical cord blood CD34-positive cells for adoptive cancer immunotherapy by Spanholtz, Jan, Tordoir, Marleen, Eissens, Diana, Preijers, Frank, van der Meer, Arnold, Joosten, Irma, Schaap, Nicolaas, de Witte, Theo M, Dolstra, Harry

“…Immunotherapy based on natural killer (NK) cell infusions is a potential adjuvant treatment for many cancers. Such therapeutic application in humans requires…”
Get full text

Mutational spectrum and dynamics of clonal hematopoiesis in anemia of older individuals by van Zeventer, Isabelle A., de Graaf, Aniek O., Wouters, Hanneke J.C.M., van der Reijden, Bert A., van der Klauw, Melanie M., de Witte, Theo, Jonker, Marianne A., Malcovati, Luca, Jansen, Joop H., Huls, Gerwin

“…Anemia is a major and currently poorly understood clinical manifestation of hematopoietic aging. Upon aging, hematopoietic clones harboring acquired…”
Get full text

Dynamic prediction of cumulative incidence functions by direct binomial regression by Grand, Mia K., de Witte, Theo J. M., Putter, Hein

“…In recent years there have been a series of advances in the field of dynamic prediction. Among those is the development of methods for dynamic prediction of…”
Get full text

Allogeneic Hematopoietic Stem-Cell Transplantation for Patients 50 Years or Older With Myelodysplastic Syndromes or Secondary Acute Myeloid Leukemia by ZIYI LIM, BRAND, Ronald, RUUTU, Tapani, BOOGAERTS, Marc, FALDA, Michele, JOUET, Jean-Pierre, NIEDERWIESER, Dietger, KROGER, Nicolaus, MUFTI, Ghulam J, DE WITTE, Theo M, MARTINO, Rodrigo, VAN BIEZEN, Anja, FINKE, Jürgen, BACIGALUPO, Andrea, BEELEN, Dietrich, DEVERGIE, Agnes, ALESSANDRINO, Emilio, WILLEMZE, Roel

“…This study was performed to examine the characteristics of transplant activity for patients with myelodysplastic syndromes (MDS) older than 50 years within the…”
Get full text

Apoptosis-Related Gene Expression Profiling in Hematopoietic Cell Fractions of MDS Patients by Langemeijer, Saskia Mc, Mariani, Niccolo, Knops, Ruth, Gilissen, Christian, Woestenenk, Rob, de Witte, Theo, Huls, Gerwin, van der Reijden, Bert A, Jansen, Joop H

“…Although the vast majority of patients with a myelodysplastic syndrome (MDS) suffer from cytopenias, the bone marrow is usually normocellular or hypercellular…”
Get full text

Chemokine induction by all-trans retinoic acid and arsenic trioxide in acute promyelocytic leukemia: triggering the differentiation syndrome by Luesink, Maaike, Pennings, Jeroen L.A., Wissink, Willemijn M., Linssen, Peter C.M., Muus, Petra, Pfundt, Rolph, de Witte, Theo J.M., van der Reijden, Bert A., Jansen, Joop H.

“…In acute promyelocytic leukemia (APL), differentiation therapy with all-trans retinoic acid (ATRA) and/or arsenic trioxide can induce a differentiation…”
Get full text

Recent advances in the understanding of iron overload in sideroblastic myelodysplastic syndrome by Cuijpers, Maria L. H., Raymakers, Reinier A. P., MacKenzie, Marius A., De Witte, Theo J. M., Swinkels, Dorine W.

“…Summary Myelodysplastic syndromes (MDS) are a heterogeneous group of clonal haematopoietic stem cell malignancies. A subgroup, the so‐called sideroblastic MDS,…”
Get full text

Risk factors for therapy-related myelodysplastic syndrome and acute myeloid leukemia treated with allogeneic stem cell transplantation by Kroger, Nicolaus, Brand, Ronald, van Biezen, Anja, Zander, Axel, Dierlamm, Judith, Niederwieser, Dietger, Devergie, Agnes, Ruutu, Tapani, Cornish, Jackie, Ljungman, Per, Gratwohl, Alois, Cordonnier, Catherine, Beelen, Dietrich, Deconinck, Eric, Symeonidis, Argiris, de Witte, Theo, Myelodysplastic Syndromes Subcommittee of The Chronic Leukaemia Working Party of European Group for Blood and Marrow Transplantation (EBMT)

“…1 Dept. for Stem Cell Transplantation, University Hospital Hamburg-Eppendorf, Germany 2 Dept. of Medical Statistics, Leiden University, Leiden, The Netherlands…”
Get full text

An alternatively spliced CXCL16 isoform expressed by dendritic cells is a secreted chemoattractant for CXCR6+ cells by Voort, Robbert, Verweij, Viviènne, Witte, Theo M., Lasonder, Edwin, Adema, Gosse J., Dolstra, Harry

“…A secreted isoform of the chemokine CXCL16 contributes to the interaction between dendritic cells and CXCR6+ lymphocytes. DC are professional APCs that…”
Get full text

Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation by Stone, Richard M, Mandrekar, Sumithra J, Sanford, Ben L, Laumann, Kristina, Geyer, Susan, Bloomfield, Clara D, Thiede, Christian, Prior, Thomas W, Döhner, Konstanze, Marcucci, Guido, Lo-Coco, Francesco, Klisovic, Rebecca B, Wei, Andrew, Sierra, Jorge, Sanz, Miguel A, Brandwein, Joseph M, de Witte, Theo, Niederwieser, Dietger, Appelbaum, Frederick R, Medeiros, Bruno C, Tallman, Martin S, Krauter, Jürgen, Schlenk, Richard F, Ganser, Arnold, Serve, Hubert, Ehninger, Gerhard, Amadori, Sergio, Larson, Richard A, Döhner, Hartmut

“…Midostaurin, an oral multitargeted kinase inhibitor, is active in patients with a FLT3 mutation. Among patients with acute myeloid leukemia and this mutation,…”
Get full text

Breast Cancer Resistance Protein in Drug Resistance of Primitive CD34+38− Cells in Acute Myeloid Leukemia by RAAIJMAKERS, Marc H. G. P, DE GROUW, Elke P. L. M, HEUVER, Leonie H. H, VAN DER REIJDEN, Bert A, JANSEN, Joop H, SCHEPER, Rik J, SCHEFFER, George L, DE WITTE, Theo J. M, RAYMAKERS, Reinier A. P

“…Purpose: Acute myeloid leukemia (AML) is considered a stem cell disease. Incomplete chemotherapeutic eradication of leukemic CD34+38− stem cells is likely to…”
Get full text

Association of anemia with health-related quality of life and survival: a large population-based cohort study by Wouters, Hanneke J C M, van der Klauw, Melanie M, de Witte, Theo, Stauder, Reinhard, Swinkels, Dorine W, Wolffenbuttel, Bruce H R, Huls, Gerwin

“…Anemia is highly prevalent, especially in older individuals. In selected populations, anemia has been reported to be associated with impaired survival and…”
Get full text

The European LeukemiaNet: achievements and perspectives by HEHLMANN, Rüdiger, GRIMWADE, David, BÜCHNER, Thomas, BURNETT, Alan, CROSS, Nicolas C. F, DE WITTE, Theo J. M, DÖHNER, Hartmut, DOMBRET, Hervé, EINSELE, Hermann, ENGELICH, Georg, FOA, Robin, FONATSCH, Christa, SIMONSSON, Bengt, GÖKBUGET, Nicola, GLUCKMAN, Elaine, GRATWOHL, Alois, GUILHOT, Francois, HAFERLACH, Claudia, HAFERLACH, Thorsten, HALLEK, Michael, HASFORD, Jörg, HOCHHAUS, Andreas, HOELZER, Dieter, APPERLEY, Jane, KILADJIAN, Jean-Jaques, LABAR, Boris, LJUNGMAN, Per, MANSMANN, Ulrich, NIEDERWIESER, Dietger, OSSENKOPPELE, Gert, RIBERA, Jose M, RIDER, Harald, SERVE, Hubert, SCHROTZ-KING, Petra, BACCARANI, Michele, SANZ, Miguel A, SAUSSELE, Susanne, BARBUI, Tiziano, BAROSI, Giovanni, BASSAN, Renato, BENE, Marie C, BERGER, Ute

“…The only way to cure leukemia is by cooperative research. To optimize research, the European LeukemiaNet integrates 105 national leukemia trial groups and…”
Get full text

Clinical-grade generation of active NK cells from cord blood hematopoietic progenitor cells for immunotherapy using a closed-system culture process by Spanholtz, Jan, Preijers, Frank, Tordoir, Marleen, Trilsbeek, Carel, Paardekooper, Jos, de Witte, Theo, Schaap, Nicolaas, Dolstra, Harry

“…Natural killer (NK) cell-based adoptive immunotherapy is a promising treatment approach for many cancers. However, development of protocols that provide large…”
Get full text

Induction of myelodysplasia by myeloid-derived suppressor cells by Chen, Xianghong, Eksioglu, Erika A, Zhou, Junmin, Zhang, Ling, Djeu, Julie, Fortenbery, Nicole, Epling-Burnette, Pearlie, Van Bijnen, Sandra, Dolstra, Harry, Cannon, John, Youn, Je-in, Donatelli, Sarah S, Qin, Dahui, De Witte, Theo, Tao, Jianguo, Wang, Huaquan, Cheng, Pingyan, Gabrilovich, Dmitry I, List, Alan, Wei, Sheng

“…Myelodysplastic syndromes (MDS) are age-dependent stem cell malignancies that share biological features of activated adaptive immune response and ineffective…”
Get full text

Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet by Malcovati, Luca, Hellström-Lindberg, Eva, Bowen, David, Adès, Lionel, Cermak, Jaroslav, del Cañizo, Consuelo, Della Porta, Matteo G., Fenaux, Pierre, Gattermann, Norbert, Germing, Ulrich, Jansen, Joop H., Mittelman, Moshe, Mufti, Ghulam, Platzbecker, Uwe, Sanz, Guillermo F., Selleslag, Dominik, Skov-Holm, Mette, Stauder, Reinhard, Symeonidis, Argiris, van de Loosdrecht, Arjan A., de Witte, Theo, Cazzola, Mario

“…Within the myelodysplastic syndrome (MDS) work package of the European LeukemiaNet, an Expert Panel was selected according to the framework elements of the…”
Get full text

Low-Dose Decitabine Versus Best Supportive Care in Elderly Patients With Intermediate- or High-Risk Myelodysplastic Syndrome (MDS) Ineligible for Intensive Chemotherapy: Final Results of the Randomized Phase III Study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group by LÜBBERT, Michael, SUCIU, Stefan, BEELDENS, Filip, MUUS, Petra, PFLÜGER, Karl-Heinz, COENS, Corneel, HAGEMEIJER, Anne, ECKART SCHAEFER, Hans, GANSER, Arnold, AUL, Carlo, DE WITTE, Theo, WIJERMANS, Pierre W, BAILA, Liliana, RÜTER, Björn Hans, PLATZBECKER, Uwe, GIAGOUNIDIS, Aristoteles, SELLESLAG, Dominik, LABAR, Boris, GERMING, Ulrich, SALIH, Helmut R

“…To compare low-dose decitabine to best supportive care (BSC) in higher-risk patients with myelodysplastic syndrome (MDS) age 60 years or older and ineligible…”
Get full text